Abstract

Continued development of existing drugs ('drug rediscovery') may offer new therapeutic options and be cost-effective. Rediscovered drugs are commonly prescribed off-label, although licensing can be important to allow safe and controlled prescription of the drugs to patients. Licensing of a new indication for a generic drug, however, is a complicated process since there is no blueprint for this and there is little interest from the pharmaceutical industry due to an unattractive cost-recovery model. In this article, we illustrate the successful license-extension for thioguanine - initially developed in 1950 for leukaemia - as a new treatment for patients with inflammatory bowel disease.

Translated title of the contributionContinued development of drugs: the path of thioguanine
Original languageDutch
Pages (from-to)D1757
JournalNederlands Tijdschrift voor Geneeskunde
Volume162
Issue number0
Publication statusPublished - 2018

Cite this

@article{689df0265b674fa2bc3542cf74b9e253,
title = "Van doorontwikkeling van een geneesmiddel tot registratie-uitbreiding",
abstract = "Continued development of existing drugs ('drug rediscovery') may offer new therapeutic options and be cost-effective. Rediscovered drugs are commonly prescribed off-label, although licensing can be important to allow safe and controlled prescription of the drugs to patients. Licensing of a new indication for a generic drug, however, is a complicated process since there is no blueprint for this and there is little interest from the pharmaceutical industry due to an unattractive cost-recovery model. In this article, we illustrate the successful license-extension for thioguanine - initially developed in 1950 for leukaemia - as a new treatment for patients with inflammatory bowel disease.",
keywords = "English Abstract, Journal Article",
author = "M Simsek and {de Boer}, {N K H} and Mulder, {C J J}",
year = "2018",
language = "Dutch",
volume = "162",
pages = "D1757",
journal = "Nederlands Tijdschrift voor Geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",
number = "0",

}

Van doorontwikkeling van een geneesmiddel tot registratie-uitbreiding. / Simsek, M; de Boer, N K H; Mulder, C J J.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 162, No. 0, 2018, p. D1757.

Research output: Contribution to journalArticleProfessional

TY - JOUR

T1 - Van doorontwikkeling van een geneesmiddel tot registratie-uitbreiding

AU - Simsek, M

AU - de Boer, N K H

AU - Mulder, C J J

PY - 2018

Y1 - 2018

N2 - Continued development of existing drugs ('drug rediscovery') may offer new therapeutic options and be cost-effective. Rediscovered drugs are commonly prescribed off-label, although licensing can be important to allow safe and controlled prescription of the drugs to patients. Licensing of a new indication for a generic drug, however, is a complicated process since there is no blueprint for this and there is little interest from the pharmaceutical industry due to an unattractive cost-recovery model. In this article, we illustrate the successful license-extension for thioguanine - initially developed in 1950 for leukaemia - as a new treatment for patients with inflammatory bowel disease.

AB - Continued development of existing drugs ('drug rediscovery') may offer new therapeutic options and be cost-effective. Rediscovered drugs are commonly prescribed off-label, although licensing can be important to allow safe and controlled prescription of the drugs to patients. Licensing of a new indication for a generic drug, however, is a complicated process since there is no blueprint for this and there is little interest from the pharmaceutical industry due to an unattractive cost-recovery model. In this article, we illustrate the successful license-extension for thioguanine - initially developed in 1950 for leukaemia - as a new treatment for patients with inflammatory bowel disease.

KW - English Abstract

KW - Journal Article

M3 - Article

VL - 162

SP - D1757

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

IS - 0

ER -